(Reuters) -Shares in European vaccine makers fell on Friday after U.S. President-elect Donald Trump picked Robert F. Kennedy ...

Nov 12 (Reuters) - Novavax (NVAX.O), opens new tab cut its annual ... the news and media division of Thomson Reuters, is the ...

The selection of vaccine sceptic Robert F Kennedy Jr by US President-elect Donald Trump to head the Department of Health and ...

TD Cowen lowered the firm’s price target on Novavax (NVAX) to $9 from $14 and keeps a Hold rating on the shares. The firm said the FDA ...

BofA lowered the firm’s price target on Novavax (NVAX) to $12 from $14 and keeps a Neutral rating on the shares. The company announced ...

Novavax said on Tuesday that it has entered into a termination and settlement agreement with the UK Health Security Agency ...

In the run-up to the US election and in the days since, a dormant market narrative awoke. Small-caps, which had a lively but shortlived rally back in July, have surged since mid-October, outperforming ...

Novavax is already poised to benefit from a separate combined Covid-flu vaccine via a deal with Sanofi announed earlier this year. Under the $1.4 billion co-licensing agreement, announced in May, ...

Novavax shares dropped Tuesday morning after the company slashed its full-year outlook when it announced its third-quarter results.

Novavax Inc. closed $15.40 short of its 52-week high ($23.86), which the company achieved on June 6th. Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated ...